Market Overview

UPDATE: Susquehanna Financial Group Initiates Coverage On BorgWarner On Attractive Entry Point

Share:

In a report published Tuesday, Susquehanna Financial Group analyst Matthew Stover initiated coverage on BorgWarner (NYSE: BWA) with a Positive rating and $67.00 price target.

In the report, Susquehanna Financial Group noted, “In our view, BWA is one of the best ways to play tightening emissions/fuel efficiency standards on a global basis. The company fosters a culture of innovation and carries itself with a blue collar ethos. BWA helps define vehicle efficiency strategies, but from a shareholders perspective it is the standout with respect to cashflow conversion and capital efficiency in the auto supplier sector. The recent pull back in the shares, in our view, provides investors with an attractive entry point to consider investment in the shares.”

BorgWarner closed on Monday at $54.59.

Latest Ratings for BWA

DateFirmActionFromTo
Nov 2019DowngradesOutperformPeer Perform
Nov 2019MaintainsOverweight
Nov 2019MaintainsOutperform

View More Analyst Ratings for BWA
View the Latest Analyst Ratings

Posted-In: Matthew Stover Susquehanna Financial GroupAnalyst Color Initiation Analyst Ratings

 

Related Articles (BWA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CAAPOppenheimerDowngrades
ROSTMKM PartnersMaintains121.0
STAYNomuraDowngrades15.0
ROKUMacquarieMaintains170.0
BJDeutsche BankMaintains27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Coca-Cola Posts Downbeat Q3 Revenue, Shares Fall

Agios Pharma Reports Initiation of Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with IDH2 Mutation